Cargando…

Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function

Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by pyrrolizidine alkaloids(PAs)-containing herbals. In this study, the aim of our study was to investigate the imaging features of PAs-induced HSOS on gadoxetic acid-enhanced magnetic resonance imaging (MRI), susceptibility-weighted imagin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Tingting, Li, Xin, Yang, Xiaoqian, Kong, Xiangquan, Liu, Hui, Bai, Tao, Xu, Keshu, Ye, Jin, Song, Yuhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362127/ https://www.ncbi.nlm.nih.gov/pubmed/30718698 http://dx.doi.org/10.1038/s41598-018-37775-1

Ejemplares similares

Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome
por: Kan, Xuefeng, et al.
Publicado: (2016)

Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China
por: Shang, Haitao, et al.
Publicado: (2021)

Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study
por: Liu, Fang, et al.
Publicado: (2020)

Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome
por: Zhou, Chun-Ze, et al.
Publicado: (2020)

Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid
por: Tu, Hongfei, et al.
Publicado: (2022)

Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
por: Zhang, Wei, et al.
Publicado: (2021)

Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids
por: Du, Xiaofei, et al.
Publicado: (2023)

Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes
por: Yang, Xiao-Qian, et al.
Publicado: (2019)

Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids
por: Luo, Shihua, et al.
Publicado: (2018)

Quantitative Analysis of CT Images in Patients with Pyrrolizidine Alkaloid-Induced Sinusoidal Obstruction Syndrome
por: Wang, Chao, et al.
Publicado: (2019)

Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome
por: Gao, Hong, et al.
Publicado: (2015)

Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wu, Fan, et al.
Publicado: (2021)

Metabolic Toxification of 1,2-Unsaturated Pyrrolizidine Alkaloids Causes Human Hepatic Sinusoidal Obstruction Syndrome: The Update
por: Teschke, Rolf, et al.
Publicado: (2021)

Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports
por: Jiang, Minjie, et al.
Publicado: (2020)

Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wang, Xuan, et al.
Publicado: (2022)

Blood microRNA Signatures Serve as Potential Diagnostic Biomarkers for Hepatic Sinusoidal Obstruction Syndrome Caused by Gynura japonica Containing Pyrrolizidine Alkaloids
por: Wang, Xunjiang, et al.
Publicado: (2021)

A TMT-based shotgun proteomics uncovers overexpression of thrombospondin 1 as a contributor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
por: Wang, Weiqian, et al.
Publicado: (2022)

Hepatic Venous Occlusion Type of Budd–Chiari Syndrome versus Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstructive Syndrome: A Multi-Center Retrospective Study
por: Tong, Yaru, et al.
Publicado: (2023)

Optimization of hepatobiliary phase imaging in gadoxetic acid-enhanced magnetic resonance imaging: a narrative review
por: Wang, Chao, et al.
Publicado: (2023)

Hepatotoxicity of Pyrrolizidine Alkaloid Compound Intermedine: Comparison with Other Pyrrolizidine Alkaloids and Its Toxicological Mechanism
por: Wang, Ziqi, et al.
Publicado: (2021)

Pyrrolizidine alkaloid-derived DNA adducts are common toxicological biomarkers of pyrrolizidine alkaloid N-oxides
por: He, Xiaobo, et al.
Publicado: (2017)

Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
por: Ricke, Jens, et al.
Publicado: (2020)

Pyrrolizidine Alkaloids in Food on the Italian Market
por: Peloso, Mariantonietta, et al.
Publicado: (2023)

Gut microbiota-derived tryptophan metabolites alleviate liver injury via AhR/Nrf2 activation in pyrrolizidine alkaloids-induced sinusoidal obstruction syndrome
por: Shang, Haitao, et al.
Publicado: (2023)

A Case of Hyperintense Liver Metastases of Breast Cancer in the Hepatobiliary Phase on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging
por: Yamaguchi, Tomoyuki, et al.
Publicado: (2020)

Pseudo-random Trajectory Scanning Suppresses Motion Artifacts on Gadoxetic Acid-enhanced Hepatobiliary-phase Magnetic Resonance Images
por: Nakamura, Yuko, et al.
Publicado: (2019)

Characterization and Lifetime Dietary Risk Assessment of Eighteen Pyrrolizidine Alkaloids and Pyrrolizidine Alkaloid N-Oxides in New Zealand Honey
por: Pearson, Andrew J., et al.
Publicado: (2021)

Defensive properties of pyrrolizidine alkaloids against microorganisms
por: Joosten, Lotte, et al.
Publicado: (2010)

Pyrrolizidine Alkaloid Extraction and Analysis: Recent Updates
por: Al-Subaie, Sarah F., et al.
Publicado: (2022)

Pyrrolizidine Alkaloids: The Botanical Origin of Pollen Collected during the Flowering Period of Echium vulgare and the Stability of Pyrrolizidine Alkaloids in Bee Bread
por: Kast, Christina, et al.
Publicado: (2019)

Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition
por: Ulloa, Jose L, et al.
Publicado: (2013)

Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?
por: Plaikner, M., et al.
Publicado: (2018)

Does Hepatic Steatosis Influence the Detection Rate of Metastases in the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI?
por: Steffen, Ingo G., et al.
Publicado: (2020)

Retrorsine Cooperates with Gut Microbiota to Promote Hepatic Sinusoidal Obstruction Syndrome by Disrupting the Gut Barrier
por: Xiao, Li, et al.
Publicado: (2022)

Identification of Toxic Pyrrolizidine Alkaloids and Their Common Hepatotoxicity Mechanism
por: Yan, Xinmiao, et al.
Publicado: (2016)

Pyrrolizidine Alkaloids: Chemistry, Pharmacology, Toxicology and Food Safety
por: Moreira, Rute, et al.
Publicado: (2018)

Hepatotoxicity of pyrrolizidine alkaloids in rats in relation to human exposure
por: Bolt, Hermann M.
Publicado: (2020)

Structure-Dependent Toxicokinetics of Selected Pyrrolizidine Alkaloids In Vitro
por: Buchmueller, Julia, et al.
Publicado: (2022)

Pyrrolizidine Alkaloids from Monofloral and Multifloral Italian Honey
por: Roncada, Paola, et al.
Publicado: (2023)

In vitro biotransformation of pyrrolizidine alkaloids in different species: part II—identification and quantitative assessment of the metabolite profile of six structurally different pyrrolizidine alkaloids
por: Geburek, Ina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cinas2k66ogg768j5hun1a62vp